Novavax (NVAX) closed the latest trading day at $10.07, indicating a -1.76% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.16% for the day. At the same time, the Dow lost 0.37%, and the tech-heavy Nasdaq gained 0.78%. Shares of the vaccine maker have depreciated by 18.84% over the course of the past month, underperforming the Medical sector's loss of 4.09% and the S&P 500's gain of 1.67%. Investors will be eagerly watching for the performance of Nov ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or “the Company”) (NASDAQ: NVAX). Investors who purchased Novavax securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/NVAX. Investigation Details On October 16, 2024, Novavax issued a press release “announc[ing] that the U.S. Food and Drug Adminis ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this vaccine maker have returned -21.2% over the past month versus the Zacks S&P 500 composite's +4.5% change. The Zacks Medical - Biomedical and Genetics industry, to which Novavax belongs, has lost 1.5% over this period. Now the key question is: Where could the stock be headed in the near term?While media ...

Let's look beyond this piece of bad news from regulators.Vaccine maker Novavax (NVAX -1.64%) has had a rollercoaster of a year. In May, the company's shares soared after it announced a lucrative agreement with biotech giant Sanofi. It's been mostly downhill for Novavax since then, though that's likely due to some profit taking by investors.However, Novavax's shares recently dropped by about 20% in one day after it announced a clinical setback. The biotech's stock price is still up by more than 100% for the ...

Key Takeaways The Food and Drug Administration put clinical holds on Novavax's COVID-19 and flu combination vaccine and its standalone flu shot because of safety concerns. The moves came as one patient who took the combination shot reported nerve damage. The company said it was working with the FDA to get the information necessary to resolve the issue and allow the company to move forward with testing. Novavax (NVAX) shares plummeted nearly 20% Wednesday after the Food and Drug Administration (FDA) stopped ...

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Novavax on Wednesday said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and influenza and a standalone flu vaccine, sending the company's shares down sharply. The biotech company's stock fell nearly 20% on Wednesday. The so-called clinical hold is due to a single rep ...

Core Viewpoint - Novavax's stock performance shows a positive shift, with upcoming earnings expected to reveal significant year-over-year growth despite a decline in revenue [1][3][4]. Company Performance - Novavax's stock closed at $12.91, reflecting a gain of 1.77% in the latest trading session, outperforming the S&P 500, which fell by 0.21% [1]. - Over the past month, Novavax shares increased by 3.17%, while the Medical sector experienced a loss of 3.28% and the S&P 500 gained 5.94% [2]. Earnings Projections - For the upcoming earnings report, Novavax is projected to report earnings of -$0.89 per share, indicating a year-over-year growth of 29.37% [3]. - The Zacks Consensus Estimate for revenue is $52.32 million, which represents a significant decline of 72.02% compared to the previous year [3]. - For the entire fiscal year, earnings are expected to be -$0.97 per share, with revenue projected at $751.97 million, reflecting changes of +82.07% and -23.56% respectively from the prior year [4]. Analyst Estimates - Recent adjustments to analyst estimates for Novavax are crucial as they indicate changing business trends, with positive revisions suggesting a favorable outlook on the company's health and profitability [5]. - The Zacks Rank system, which incorporates these estimate changes, currently ranks Novavax at 3 (Hold), with a recent upward shift of 6.28% in the EPS estimate [7]. Industry Context - Novavax operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 84, placing it in the top 34% of over 250 industries [7].

Shares of Novavax (NVAX, Financial), a biotechnology firm specializing in vaccine development, experienced a significant drop of 5.11%. The stock is currently priced at $12.92 with a trading volume of approximately 3.03 million shares, reflecting a turnover rate of 1.89% and a price fluctuation of 6.10%. Recent financial data reveals Novavax achieved a revenue of $415 million, net earnings of $162 million, and earnings per share of $1.09. The company's gross profit stands at $379 million, with a price-to-ea ...

Ruxandra Draghia-Akli, MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organization Dr. Draghia-Akli will be integral in strategically evaluating the Company's pipeline and opportunities for its Matrix-M™ adjuvant and protein-based technology platform GAITHERSBURG, Md., Sept. 25, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvan ...

The latest trading session saw Novavax (NVAX) ending at $12.80, denoting a -0.85% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.28%. Meanwhile, the Dow experienced a rise of 0.15%, and the technology-dominated Nasdaq saw an increase of 0.15%. Coming into today, shares of the vaccine maker had gained 7.67% in the past month. In that same time, the Medical sector gained 0.38%, while the S&P 500 gained 2%. The upcoming earnings release of Novavax will b ...